Shuai Zhu, Jun Yuan, Feng Ju, Mengmeng Gu, Ze Xiang, Yan Zhang
{"title":"γ -谷氨酰转肽酶与血小板比值：预测戊型肝炎病毒相关急性肝衰竭患者发生和预后的良好无创生物标志物","authors":"Shuai Zhu, Jun Yuan, Feng Ju, Mengmeng Gu, Ze Xiang, Yan Zhang","doi":"10.3389/fmed.2025.1573114","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The relationship between GPR and hepatitis E has not been reported. This study evaluates the GPR levels in AHE patients and HEV-ALF patients and explores the role of GPR levels in the prognosis of HEV-ALF patients, offering new strategies and methods for the diagnosis and prognosis of HEV-ALF patients.</p><p><strong>Methods: </strong>Serum samples were collected from 206 AHE patients and 217 HEV-ALF patients admitted to the First Affiliated Hospital of Zhejiang University School of Medicine, Suzhou Yongding Hospital, and Nanjing Medical University Affiliated Suzhou Hospital between January 1, 2017, and November 30, 2024.</p><p><strong>Results: </strong>The GPR level in the HEV-ALF group was significantly higher than in the AHE group (<i>p</i> < 0.001). OPLS-DA analysis revealed that INR, TBIL, PLT, GPR, TCH, ALT, AFP, TP, ALB, and AST were the major influential factors for the occurrence of HEV-ALF. GPR showed good diagnostic performance with an AUC of 0.701. DCA further supported the utility of GPR across a range of threshold probabilities. Regarding the prediction of 30-day mortality, GPR levels were significantly higher in the non-survival group compared to the survival group (<i>p</i> < 0.001). OPLS-DA analysis highlighted GPR as the most influential factor for predicting 30-day mortality. GPR demonstrated an AUC of 0.703. DCA results also indicated GPR's strong decision-making ability for predicting 30-day mortality in HEV-ALF patients.</p><p><strong>Conclusion: </strong>GPR is highly expressed in HEV-ALF patients and is closely related to their prognosis.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1573114"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973331/pdf/","citationCount":"0","resultStr":"{\"title\":\"The gamma-glutamyl transpeptidase to platelet ratio: a good noninvasive biomarker for predicting for the occurrence and prognosis of patients with hepatitis E virus-related acute liver failure.\",\"authors\":\"Shuai Zhu, Jun Yuan, Feng Ju, Mengmeng Gu, Ze Xiang, Yan Zhang\",\"doi\":\"10.3389/fmed.2025.1573114\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The relationship between GPR and hepatitis E has not been reported. This study evaluates the GPR levels in AHE patients and HEV-ALF patients and explores the role of GPR levels in the prognosis of HEV-ALF patients, offering new strategies and methods for the diagnosis and prognosis of HEV-ALF patients.</p><p><strong>Methods: </strong>Serum samples were collected from 206 AHE patients and 217 HEV-ALF patients admitted to the First Affiliated Hospital of Zhejiang University School of Medicine, Suzhou Yongding Hospital, and Nanjing Medical University Affiliated Suzhou Hospital between January 1, 2017, and November 30, 2024.</p><p><strong>Results: </strong>The GPR level in the HEV-ALF group was significantly higher than in the AHE group (<i>p</i> < 0.001). OPLS-DA analysis revealed that INR, TBIL, PLT, GPR, TCH, ALT, AFP, TP, ALB, and AST were the major influential factors for the occurrence of HEV-ALF. GPR showed good diagnostic performance with an AUC of 0.701. DCA further supported the utility of GPR across a range of threshold probabilities. Regarding the prediction of 30-day mortality, GPR levels were significantly higher in the non-survival group compared to the survival group (<i>p</i> < 0.001). OPLS-DA analysis highlighted GPR as the most influential factor for predicting 30-day mortality. GPR demonstrated an AUC of 0.703. DCA results also indicated GPR's strong decision-making ability for predicting 30-day mortality in HEV-ALF patients.</p><p><strong>Conclusion: </strong>GPR is highly expressed in HEV-ALF patients and is closely related to their prognosis.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1573114\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973331/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1573114\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1573114","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：GPR与戊型肝炎的关系尚未见报道。本研究通过对AHE患者和HEV-ALF患者GPR水平的评价，探讨GPR水平在HEV-ALF患者预后中的作用，为HEV-ALF患者的诊断和预后提供新的策略和方法。方法：收集2017年1月1日至2024年11月30日在浙江大学医学院第一附属医院、苏州永定医院和南京医科大学附属苏州医院住院的206例AHE患者和217例HEV-ALF患者的血清样本。结果：HEV-ALF组GPR水平明显高于AHE组（p p ）。结论：GPR在HEV-ALF患者中高表达，且与预后密切相关。
The gamma-glutamyl transpeptidase to platelet ratio: a good noninvasive biomarker for predicting for the occurrence and prognosis of patients with hepatitis E virus-related acute liver failure.
Background: The relationship between GPR and hepatitis E has not been reported. This study evaluates the GPR levels in AHE patients and HEV-ALF patients and explores the role of GPR levels in the prognosis of HEV-ALF patients, offering new strategies and methods for the diagnosis and prognosis of HEV-ALF patients.
Methods: Serum samples were collected from 206 AHE patients and 217 HEV-ALF patients admitted to the First Affiliated Hospital of Zhejiang University School of Medicine, Suzhou Yongding Hospital, and Nanjing Medical University Affiliated Suzhou Hospital between January 1, 2017, and November 30, 2024.
Results: The GPR level in the HEV-ALF group was significantly higher than in the AHE group (p < 0.001). OPLS-DA analysis revealed that INR, TBIL, PLT, GPR, TCH, ALT, AFP, TP, ALB, and AST were the major influential factors for the occurrence of HEV-ALF. GPR showed good diagnostic performance with an AUC of 0.701. DCA further supported the utility of GPR across a range of threshold probabilities. Regarding the prediction of 30-day mortality, GPR levels were significantly higher in the non-survival group compared to the survival group (p < 0.001). OPLS-DA analysis highlighted GPR as the most influential factor for predicting 30-day mortality. GPR demonstrated an AUC of 0.703. DCA results also indicated GPR's strong decision-making ability for predicting 30-day mortality in HEV-ALF patients.
Conclusion: GPR is highly expressed in HEV-ALF patients and is closely related to their prognosis.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
